^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ETP-47187

    i
    Associations
    News

    Trials

    Company:
    CNIO
    Drug class:
    mTOR inhibitor, PI3K inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study (NCT04890236)
    Phase 1
    Emory University
    Completed
    Last update posted :
    01/20/2025
    Initiation :
    01/13/2022
    Primary completion :
    03/20/2024
    Completion :
    09/04/2024
    CD27
    |
    Copiktra (duvelisib) • Kymriah (tisagenlecleucel-T) • ETP-47187
    Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT03961672)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/15/2024
    Initiation :
    05/13/2020
    Primary completion :
    06/27/2024
    Completion :
    06/27/2024
    BCL2 • CCND1 • FCER2
    |
    Chr t(11;14) • CCND1 overexpression
    |
    Copiktra (duvelisib) • ETP-47187